Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01484015 · ClinicalTrials.gov registry record · Phase 1
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT01484015 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 70 participants.
The verdict
NCT01484015, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This randomized pilot clinical trial studies how well giving prolonged infusion compared to standard infusion of cefepime hydrochloride works in treating patients with febrile neutropenia. Giving cefepime hydrochloride over a longer period of time may be more effective than giving cefepime hydrochloride over the standard time.
Interventions
- DRUG cefepime hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01484015
The ClinicalTrials.gov registry entry for NCT01484015 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cefepime hydrochloride is the first listed.
NCT01484015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01484015 about?
NCT01484015 is a clinical study titled "Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia". This randomized pilot clinical trial studies how well giving prolonged infusion compared to standard infusion of cefepime hydrochloride works in treating patients with febrile neutropenia. Giving cefepime hydrochloride over a longer period of time may be more effective than giving cefepime hydrochlo...
What is the current status of trial NCT01484015?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2011-02. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01484015?
The interventions under investigation include: cefepime hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01484015?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.